A Grim Picture, No Matter How You Look At It
This article was originally published in RPM Report
Executive Summary
FDA's official list of New Molecular Enitity approvals is increasingly unsatisfactory as a benchmark for analyzing the health of drug development. To address that problem, The RPM Report creates a tally of Innovative Commercial Therapies. By that analysis, the drug approval trends come into sharper focust. But the picture still isn't pretty.